| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
100.60(B) |
| Last
Volume: |
14,535,649 |
Avg
Vol: |
11,963,293 |
| 52
Week Range: |
$43.67 - $69.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
18,718 |
681,397 |
| Total Sell Value |
$0 |
$0 |
$1,146,397 |
$49,727,684 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
12 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ahmed Nadim |
EVP and President, Hematology |
• – – |
2020-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,594 |
34,983 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2020-12-02 |
4 |
D |
$62.18 |
$280,183 |
D/D |
(4,506) |
42,208 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2020-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
46,714 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2020-12-02 |
4 |
D |
$62.18 |
$80,772 |
D/D |
(1,299) |
22,371 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2020-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,637 |
23,670 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2020-12-02 |
4 |
D |
$62.18 |
$316,310 |
D/D |
(5,087) |
58,487 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2020-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
63,574 |
|
- |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2020-12-01 |
4 |
D |
$62.41 |
$60,413 |
D/D |
(968) |
4,391 |
|
- |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2020-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,825 |
5,359 |
|
- |
|
| Von Autenried Paul |
EVP, Chief Information Officer |
• – – |
2020-11-25 |
4 |
S |
$63.50 |
$191 |
D/D |
(3) |
126,698 |
|
1% |
|
| Dubow Adam |
SVP,ChiefCompliance&EthicsOff. |
• – – |
2020-11-24 |
4 |
S |
$63.39 |
$57,051 |
D/D |
(900) |
15,186 |
|
2% |
|
| Von Autenried Paul |
EVP, Chief Information Officer |
• – – |
2020-11-24 |
4 |
S |
$62.75 |
$1,255,000 |
D/D |
(20,000) |
126,701 |
|
2% |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2020-11-23 |
4 |
S |
$61.34 |
$823,244 |
D/D |
(13,421) |
37,922 |
|
-0% |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2020-11-19 |
4 |
S |
$61.25 |
$3,530,269 |
D/D |
(57,591) |
51,343 |
|
-1% |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2020-11-19 |
4 |
OE |
$38.41 |
$2,572,887 |
D/D |
52,213 |
98,355 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2020-10-30 |
4 |
D |
$58.45 |
$167,109 |
D/D |
(2,859) |
56,721 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2020-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,804 |
59,580 |
|
- |
|
| Ahmed Nadim |
EVP and President, Hematology |
• – – |
2020-10-30 |
4 |
D |
$58.45 |
$133,909 |
D/D |
(2,291) |
28,389 |
|
- |
|
| Ahmed Nadim |
EVP and President, Hematology |
• – – |
2020-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,650 |
30,680 |
|
- |
|
| Rice Derica W |
Director |
– • – |
2020-09-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,200 |
|
6% |
|
| Santiago Karen Murphy |
SVP & Controller |
• – – |
2020-09-01 |
4 |
D |
$60.97 |
$13,413 |
D/D |
(220) |
8,170 |
|
- |
|
| Santiago Karen Murphy |
SVP & Controller |
• – – |
2020-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
642 |
8,390 |
|
- |
|
| Caforio Giovanni |
Chairman and CEO |
• • – |
2020-08-31 |
4 |
S |
$62.70 |
$2,497,968 |
D/D |
(39,840) |
445,584 |
|
-5% |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2020-08-17 |
4 |
S |
$64.00 |
$340,928 |
D/D |
(5,327) |
2,534 |
|
3% |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2020-08-13 |
4 |
S |
$63.24 |
$8,943,401 |
D/D |
(141,420) |
432,744 |
|
3% |
|
2225 Records found
|
|
Page 12 of 89 |
|
|
0.35 (0.78%) 
